NASDAQ:MCRB

Seres Therapeutics Q1 2026 Earnings Results & Report

Seres Therapeutics logo
$1.44 +0.03 (+2.13%)
Closing price 04:00 PM Eastern
Extended Trading
$1.43 -0.01 (-0.62%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Seres Therapeutics missed analyst earnings expectations and met on revenue in its Q1 2026 results, released May 5, 2026. The company reported EPS of -$2.08 versus the -$1.88 consensus estimate, while revenue of $358 thousand matched the $358 thousand estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Seres Therapeutics EPS Results

Actual EPS
-$2.08
Consensus EPS
-$1.88
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Seres Therapeutics Revenue Results

Actual Revenue
$358 thousand
Expected Revenue
$358 thousand
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Seres Therapeutics Q1 2026 Earnings FAQ

Seres Therapeutics (NASDAQ:MCRB) reported earnings of -$2.08 per share for Q1 2026, missing the consensus estimate of -$1.88. The report was announced on Tuesday, May 5, 2026.

Seres Therapeutics reported revenue of $358 thousand for Q1 2026, against a consensus estimate of $358 thousand.

Seres Therapeutics Earnings Headlines

Equities Analysts Set Expectations for MCRB FY2026 Earnings
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Seres Therapeutics: Q3 earnings snapshot
See More Seres Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Seres Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your email.

About Seres Therapeutics

Seres Therapeutics (NASDAQ:MCRB) is a biotechnology company based in Cambridge, Massachusetts, focused on developing microbiome-based medicines. Its approach uses live biotherapeutic products designed to influence the gut microbiome and address conditions including infections and complications associated with impaired immune function.

The company developed VOWST, an oral microbiota-based therapy approved in the United States to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment. Seres developed the product in collaboration with Nestlé Health Science, which acquired rights to VOWST.

Seres has also advanced investigational candidates such as SER-155, an oral live biotherapeutic being studied for potential use in people at risk of infections related to immune suppression. The company’s research builds on its work in microbiome science and therapeutic development.

View Seres Therapeutics Profile